It’s no secret that Click Therapeutics is on a roll with pharma partnerships. The mental health-focused digital therapeutic company made headlines this week when it announced a new clinical trial with Japanese pharma company Otsuka, based on a deal made in 2019.
But this isn't the only deal the New York-based company worked on with the life science industry. In September, the company signed a $...
Highmark, a Blue Cross Blue Shield-affiliated health insurer, will expand access to Freespira's digital therapeutic for PTSD, panic disorder, panic attacks and other panic symptoms.
In addition to bringing the treatment to members living in Pennsylvania, Delaware and West Virginia, the agreement will also provide remote coaching on how to use Freespira to those not already receiving support from...
International pharma Boehringer Ingelheim and prescription digital therapeutics company Click Therapeutics have inked a $500 million-plus deal to jointly develop and commercialize a digital treatment for patients with schizophrenia.
The treatment, referred to as CT-155, will be a mobile app built on Click's proprietary tech platform, the companies said.
Employing cognitive and neurobehavioral...
Photo by Oscar & Associates
This week saw the kickoff of HIMSS19, and the MobiHealthNews staff was on site to interview industry leaders and catch the latest insights from a range of health and tech experts. While the majority of MobiHealthNews' stories and videos from the show floor can be found on our HIMSS19 conference coverage page, there was no shortage of digital product launches, deals and other announcement ...
Medication management and adherence app maker Medisafe has announced a partnership with Boehringer Ingelheim following a successful pilot.
Medisafe will offer a wraparound app experience that incorporates Pradaxa-specific educational information into a special version of its app, which patients will be directed to when they're prescribed the drug.
"Pradaxa is not different than any other...
Following a successful nine-month pilot, Boehringer Ingelheim and HealthPrize Technologies announced that the digital adherence support program RespiPoints will be expanded to any patient who is taking certain Boehringer Ingelheim medications, including some available in the Respimat inhaler.
Launched in 2016, the web- and mobile-based RespiPoints program offers patients a variety of adherence-...
Pharma companies are as excited as anyone about the shift to value-based care and the ways that technology can enable it, but they’re increasingly skeptical about the speed of that change. At Health 2.0 this week in Santa Clara, California, at a panel moderated by Kian Beyzavi, principal investor at KBeyzavi and Associates, several innovation executives at pharmaceuticals talked about value-based...
By way of a contract with UK-based healthcare startup Cera, Uber will help facilitate faster patient care to those in England's National Health Service system by providing on-demand transportation for caregivers and patients between hospitals and homes. Cera originally launched the caregiver-patient matching service in November with a few smaller clinical organizations, and Uber acts as the...
About the author: Naomi Fried, PhD (@NaomiFried), is the CEO of Health Innovation Strategies, which provides digital health strategy and innovation infrastructure consulting to healthcare stakeholders including pharma companies and providers. Her previous positions include the first Chief Innovation Officer at Boston Children’s Hospital, Biogen’s VP of Innovation and External Partnerships, and VP...
Pharmaceutical company Boehringer Ingelheim is partnering with Inovalon, a data analytics company that provides cloud-based platforms to the healthcare industry to facilitate the shift from volume to value-based care, on behalf of Boehringer Ingelheim’s diabetes alliance with Eli Lilly. Leveraging Inovalon’s platform, the partnership will work to support outcomes-based contracting, taking...
